45
Participants
Start Date
August 7, 2023
Primary Completion Date
September 26, 2025
Study Completion Date
September 26, 2025
BAY2862789
Oral administration, solution or tablets
The Kinghorn Cancer Centre - Medical Oncology Department, Darlinghurst
Seoul National University Hospital, Seoul
Princess Alexandra Hospital Australia, QLD
Chungbuk National University Hospital, Cheongju-si
Hospital Universitario Virgen De La Victoria - Oncology, Málaga
AdventHealth medical Group Oncology Research at Celebration, Celebration
Cancer Center and Research Institute - UMMC, Jackson
Brigette Harris Cancer Pavilion at Henry Ford Cancer Center - Detroit, Detroit
Gyeongsang National University Hospital, Jinju
The University of Texas MD Anderson Cancer Center - Texas Medical Center, Houston
Jilin Cancer Hospital, Changchun
Tongji Hosp. of Tongji Med Coll, Huazhong Uni of Sci & Tech., Wuhan
Tel-Aviv Sourasky Medical Center, Tel Aviv
Hadassah Hebrew University Hospital Ein Kerem, Jerusalem
"START , San Antonio"
Asan Medical Center - Oncology Department, Seoul
The Catholic University of Korea Seoul St. Mary's Hospital, Seoul
Hospital Universitari Vall d'Hebron - Institut d'Oncologia - Grupo de Tumores Toracicos y Cancer de Cabeza y Cuello, Barcelona
Lead Sponsor
Bayer
INDUSTRY